At a forum Thursday, pharma leaders expressed resistance to a voluntary WHO pool to collect patent rights that could be useful in the pandemic response.
The FDA found traces of NDMA in extended-release versions of metformin — but not in immediate-release versions — and has asked manufacturers to take action.
When chronic myeloid leukemia (CML) treatments fail — addressing resistance and intolerance
Treatment failure is a hurdle that many people living with CML face throughout their journey. Up to 24% of CML patients switch their initial TKI therapy due to resistance or intolerance. This makes it critical for the medical community to be aware that additional treatment options are available when patients can no longer take their initial TKI, because of side effects or lack of response. Learn more about hurdles in CML treatment and potential solutions here.
An early stage vaccine is drawing interest from James Wilson, a gene therapy pioneer, as well as AveXis, the gene therapy unit of the drug giant Novartis.
